Table 1.
Characteristics of patient population
| Baseline | 6-month follow-up time point | 12-month follow-up time point | 18-month follow-up time point | 24-month follow-up time point | |
|---|---|---|---|---|---|
| Number of subjects | 57 | 57 | 45 | 41 | 37 |
| Median Age in years (range) | 9 (4 – 18) | 9 (4 – 18) | 9 (4 – 18) | 9 (4 - 18) | 9 (4 – 18) |
| Male | 35 (61%) | 35 (61%) | 25 (56%) | 24 (58%) | 22 (59%) |
| Ethnicity | |||||
| Caucasian | 30 (53%) | 30 (53%) | 25 (55%) | 23 (56%) | 20 (54%) |
| Asian | 18 (32%) | 17 (32%) | 13 (29%) | 11 (27%) | 11 (30%) |
| Indian | 5 (9%) | 5 (9%) | 5 (11%) | 5 (12%) | 5 (13%) |
| Hispanic | 3 (5%) | 3 (5%) | 2 (4%) | 2 (5%) | 1 (3%) |
| African-American | 1 (2%) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Coexisting atopic disease | |||||
| Asthma | 37 (65%) | 37 (65%) | 27 (60%) | 37 (59%) | 21 (57%) |
| Allergic Rhinitis | 30 (52%) | 30 (52%) | 25 (55%) | 20 (50%) | 20 (54%) |
| Atopic Dermatitis | 17 (30%) | 17 (30%) | 13 (30%) | 12 (30%) | 12 (32%) |
| Number of allergens | |||||
| 1 | 24 (42%) | 24 (42%) | 14 (31%) | 13 (32%) | 14 (38%) |
| 2 | 13 (23%) | 13 (23%) | 13 (29%) | 11 (27%) | 8 (22%) |
| 3 | 8 (14%) | 8 (14%) | 8 (18%) | 8 (19%) | 8 (22%) |
| 4 | 4 (7%) | 4 (7%) | 3 (6%) | 3 (7%) | 2 (5%) |
| 5 | 8 (14%) | 8 (14%) | 6 (13%) | 5 (12%) | 5 (13%) |
| Allergens | |||||
| Peanut | 48 (84%) | 47 (84%) | 38 (84%) | 33 (80%) | 31 (84%) |
| Cashew | 17 (30%) | 17 (30%) | 15 (33%) | 13 (32%) | 17 (46%) |
| Walnut | 12 (21%) | 12 (21%) | 11 (24%) | 10 (24%) | 9 (24%) |
| Egg | 12 (21%) | 12 (21%) | 10 (22%) | 11 (27%) | 8 (22%) |
| Pecan | 10 (17%) | 10 (17%) | 9 (20%) | 8 (19%) | 8 (22%) |
| Milk | 8 (14%) | 8 (14%) | 7 (15%) | 7 (17%) | 6 (16%) |
| Almond | 6 (10%) | 6 (10%) | 5 (11%) | 5 (12%) | 5 (13%) |
| Sesame | 4 (7%) | 4 (7%) | 4 (9%) | 4 (10%) | 4 (11%) |
| Hazelnut | 3 (5%) | 3 (5%) | 3 (7%) | 2 (5%) | 1 (3%) |
| Shellfish | 3 (5%) | 3 (5%) | 1 (2%) | 1 (2%) | 1 (3%) |
Demographics and clinical characteristics of patients are shown at baseline, 6-month follow-up, 12-month follow-up, 18-month follow-up, and 24-month follow-up time point.